Just the Facts: Adverse events associated with immune checkpoint inhibitor treatment for cancer
- 1 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in CJEM
- Vol. 22 (6), 749-752
- https://doi.org/10.1017/cem.2020.409
Abstract
A 64-year-old male with lung cancer presents to the emergency department with one week of cough and increasing shortness of breath. At triage, his temperature is 37.3 degrees Celsius, heart rate 106 beats per minute, blood pressure 136/80, and oxygen saturation 87% on room air, which improves to 94% with 3 L of oxygen via nasal prongs. He has a chest X-ray that demonstrates bilateral patchy infiltrates. He is treated for pneumonia with antibiotics. His respiratory status worsens, with an increasing oxygen requirement. Additional history reveals that the patient recently finished treatment for lung cancer with an immune checkpoint inhibitor.This publication has 6 references indexed in Scilit:
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019Diabetes Care, 2018
- Immune‐related Adverse Events in Cancer PatientsAcademic Emergency Medicine, 2018
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Harnessing the immune system to improve cancer therapyAnnals of Translational Medicine, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016